Cellectis stem cells, a business unit of Cellectis Group, has introduced hiPS-HEP, a human iPS derived hepatocyte product. The hiPS-HEP, with homogeneity, a long life span of stable CYP activity and reproducibility, provides a range of in ...
Tags: hiPS-HEP, iPS derived hepatocyte product, vitro applications
Novara Therapeutics, an antiviral drug discovery company, has secured $23m in Series A financing to support the development of capsid-targeting antivirals to treat chronic hepatitis B (HBV) and HIV infections. The company's antiviral ...
Tags: antiviral drug discovery company, chronic hepatitis, HIV infections
Prosetta Antiviral has entered into a multi-year collaboration with Bristol-Myers Squibb Company to further discover and develop select drug candidates representing new, novel classes of antiviral drugs. The collaboration will focus on ...
Tags: lect drug candidates, antiviral drugs, viral infections
Cancer Therapeutics has announced the validation and performance of CTx-294886 in combination with Avastin in a preclinical model of basal breast cancer. The CTx-0294886, a potent small molecule inhibitor of Focal Adhesion Kinase (FAK) ...
Tags: cancer therapeutics, CTx-294886, basal breast cancer, FAK inhibitor
Fundacion MEDINA has entered into a contract research collaboration with Cubist Pharmaceuticals to discover novel antibiotics from Cubist's and MEDINA's proprietary and natural product libraries. The alliance will be focused on going ...
Tags: Research Collaboration, Cubist's drug, anti-bacterial drugs
Astellas Pharma, a Japan-based pharmaceutical company, has announced its decision to shut down one of its subsidiaries, Urogenix, which is a research facility focusing on drug discovery in the field of urology. The company expects to ...
Tags: urology research, resource allocation, clinical potential
Vernalis has reached a research milestone as part of the oncology drug discovery alliance with French pharmaceutical company, Servier. Under the drug discovery program, Vernalis will receive a payment of €0.5m from Servier on ...
Tags: drug discovery platforms, oncology drug discovery, undisclosed oncology
Metabolon has signed a multi-year research alliance with Japan based Takeda to develop new therapeutic targets and biomarkers. Under the collaboration, Metabolon will apply its platform to discover and validate targets, and identify ...
Tags: Drug Discovery Alliance, Takeda's R&D programs, metabolomic profiling
GlaxoSmithKline (GSK) has entered into a drug discovery alliance with Yale to design a potential new class of medicines that degrade disease-causing proteins. Under the collaboration, GSK integrates its expertise in medicinal chemistry ...
Tags: Yale University, Drug Discovery Alliance, protein-degrading drug
GlaxoSmithKline (GSK) and Chiromics have partnered to discover classes of small molecules against biological targets. The collaboration will leverage Chiromics' compound collections of accessible complexity, Chalis, hit recognition ...
Tags: biological targets, classes of Small Molecules, drug discovery
DiscoveRx in Fremont, US, has purchased BioSeek, a provider of drug discovery services, for an undisclosed sum. Under the acquisition, DiscoveRx will add BioSeek's BioMAP drug screening platform to its drug discovery solutions portfolio ...
Tags: DiscoveRx, BioSeek, purchased, drug discovery services
RayBiotech, a developer of antibody and protein array technologies, has introduced a peptoid drug candidate and diagnostic ligand discovery service program. The new service platform, which is aimed at the identification of novel ligands ...
Tags: rayBiotech, peptoid, ligand, peptoid drug candidate
With downward price pressures, the excess capacity that providers must have on hand for peak traffic becomes a drag on profits. After the cloud gold-rush era is over, providers will need to find ways to turn that cost center into a profit ...
Tags: cloud service, IT industry, IT technology, SETI
The European Commission has approved Vertex Pharmaceuticals' Kalydeco (ivacaftor) to treat the underlying cause of cystic fibrosis in people with a specific genetic mutation (G551D). The approval is based on positive findings from two ...
Tags: european approval, kalydeco, cystic fibrosis
Accelrys, a scientific enterprise R&D software and services company, has purchased the web-based drug discovery information management technology, Hit Explorer Operating System (HEOS) from Scynexis. HEOS is a Software-as-a-Service (SaaS) ...
Tags: Accelrys, purchased, Hit Explorer Operating System, Scynexis, SaaS, drug